Dapacose (Dapagliflozin) is a Sodium-Glucose contransporter 2 (SGLT2) inhibitor drug, which is indicated in adults for the treatment of insufficiently controlled Type 2 Diabetes Mellitus as an adjunct to other medications as well as diet and exercise. Dapagliflozin is also used in adults for the treatment of symptomatic Chronic Heart Failure with reduced ejection fraction with or without Diabetes. The drug is also used for the treatment of Chronic Kidney Disease ( CKD) patients upto Stage III (eGFR of greater or equal to 30ml/min/1.73m2.)
Dapacose is marketed by J.B. Chemicals & Pharmaceuticals Ltd. and comes in two doses namely DAPACOSE 5mg and DAPACOSE 10mg.
Dapagliflozin inhibits the SGLT2 which is primarily located in the proximal tubule of the nephron. SGLT2 facilitates 90% of glucose reabsorption in the kidneys and so its inhibition allows for glucose to be excreted in the urine. This excretion allows for better glycemic control and potentially weight loss in patients with Type 2 Diabetes Mellitus.
Dapagliflozin is also used to reduce the risk of the need for hospitalization for Heart Failure in adults who have Type 2 Diabetes along with heart and blood vessel disease or who have multiple risk factors for developing heart and blood vessel disease. Recent evidence has also shown that the drug halts the progression of CKD in patients with, or without Diabetes.
2) To prevent the progression of Chronic Kidney Disease (CKD), Hospitalization for Heart Failure (hHF), MACE and CV death in patients with T2DM with CKD.
In Management of Type 2 Diabetes Mellitus, Dapagliflozin provides benefits beyond Glucose Control.
- a) Cardio protection
Dapagliflozin demonstrates reduction in the risk of CV death or worsening heart failure in patients with HFrEF, with & without diabetes.
- b) Renal protection
Dapagliflozin delays initiaton of dialysis & reduces the number of deaths.
Dapa-HF2 (trial) demonstrated reduction in the risk of CV death or worsening heart failure in patients with HFrEF, with & without Diabetes.
hHF#- Hospitalization for heart failure.
RRR*- Relative risk reduction.
In patients with CKD3, with and without Type 2 Diabetes, Dapagliflozin significantly
- Reduces the risk of kidney failure.
- Reduces the risk of CV death or Heart Failure ospitalization.
- Prolongs survival.
Dapagliflozin is Approved for the treatment of CKD patients up to Stage III(eGFR>30ml/min/1.73m)
1. Das,et al. JACC,2020 sep 1;76 (9): 1117-1145,John B.Buse et al. Diabetologia (2020) 63:1667
2. Huang H et al, AM J Manag Care. 2018 Apr;24( 8 Suppl):S132-S137
3. Heerspink HJL et al. N Engl J Med 2020 oct 8;383( 15): 1436-1446,Recommendations of the SEC dated 8th Jan 2021